Analysis of Resistance of Mycobacterium Tuberculosis to Different Anti-Tuberculosis Drugs

Qing Sun

Department of Basic Medicine, Hunan Traditional Chinese Medical College, Zhuzhou, 412012, China

Abstract: Tuberculosis has been one of the main infectious diseases in the world since ancient times. In the 19th century, Koho, a German scientist, isolated a then-new bacterium, mycobacterium tuberculosis, from the tissues of dead patients. Since then, the mystery of tuberculosis has been revealed. Then bacteriologists Callander and Ceran successfully developed a live attenuated vaccine that effectively prevented the onset of tuberculosis after vaccination, setting a precedent for active immunization against tuberculosis. At the begin-ning of the 20th century, streptomycin was first used in the treatment of tuberculosis, and a good curative ef-fect was obtained. From then on, a new era of tuberculosis drug chemotherapy was entered. At present, taking rifampicin, isoniazid and other chemotherapy drugs is still the most common clinical first-line anti-tuberculosis treatment. However, factors such as irregular medication, drug abuse and serious adverse drug reactions greatly increase the likelihood of drug-resistance of mycobacterium tuberculosis. This paper ana-lyzed the types of anti-tuberculosis drugs for patients with drug resistance in XXX region in 2018-2019, and looked forward to the development trend, so as to provide a basis for the subsequent clinical selection of drugs and the formulation of rational chemotherapy regiments for drug-resistant tuberculosis.

Keywords: Mycobacterium tuberculosis; Drug resistance; Anti-tuberculosis drugs